Table 1 Clinical and biochemical characteristics of subjects with and without NAFLD
NAFLD (213) | w/o NAFLD (51) | p | |
|---|---|---|---|
Age (yrs) | 54,3 ± 12 | 56,1 ± 14,4 | Ns |
Male Gender (%) | 64,6 | 63,3 | Ns |
BMI (kg/m2) | 31,6 ± 5,6 | 26,8 ± 3,6 | <0,001 |
Urinary 8-iso-PGF2α (pg/mg creatinine) | 714,4 ± 121,5 | 621,2 ± 125,9 | <0,001 |
sNOX2-dp (pg/ml) | 57,4 ± 13.6 | 47,8 ± 9.9 | <0.001 |
Adiponectin (ng/ml) | 8,5 (5/12) | 13 (8/15) | <0,001 |
Cytokeratin 18 (mIU/ml) | 180 (146/190) | 136 (125/173) | <0,001 |
ALT (IU/L) | 27,5 (20/40) | 18 (14/27) | <0,001 |
HOMA_IR | 3,5 (2,4/5,9) | 1,9 (1,3/2,3) | <0,001 |
Metabolic syndrome (%)* | 67,7 | 21,7 | <0,001 |
High fasting glucose (%)* | 53,8 | 29,8 | < 0,01 |
Hypertriglyceridemia (%)* | 46,9 | 14,6 | <0,001 |
High waist circumference (%)* | 81,9 | 42,6 | <0,001 |
Low HDL-cholesterol (%)* | 37,2 | 18,8 | < 0,05 |
High blood pressure (%)* | 84,5 | 75,5 | Ns |
Diabetes (%) | 31,1 | 12,2 | < 0,01 |
Statin use (%) | 33,5 | 42,9 | Ns |